Novel therapeutic strategies for reducing arterial stiffness

British Journal of Pharmacology

Volumn 148, Issue 7, 2006, Pages 881-883

  McEniery, Carmel M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; ACETYLCHOLINE; ALT 946; AMINOGUANIDINE; NITROPRUSSIDE SODIUM; NORADRENALIN; PYRIDOXAMINE; UNCLASSIFIED DRUG; ADVANCED GLYCATION END PRODUCT; CARDIOVASCULAR AGENT; GUANIDINE DERIVATIVE;

ARTERY DIAMETER; ARTERY WALL; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; LIPID STORAGE; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; ARTERY; METABOLISM; PATHOLOGY;

ARTERIES; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; HYPERTENSION;

EID: 33749338151     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706805     Document Type: Note

References (26)

1. ASIF, M., EGAN, J., VASAN, S., JYOTHIRMAYI, G.N., MASUREKAR, M.R., LOPEZ, S., WILLIAMS, C., TORRES, R.L., WAGLE, D., ULRICH, P., CERAMI, A., BRINES, M. & REGAN, T.J. (2000). An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc. Natl. Acad. Sci. U.S.A., 97, 2809-2813.
2. BLACHER, J., GUERIN, A.P., PANNIER, B., MARCHAIS, S.J., SAFAR, M. & LONDON, G. (1999). Impact of aortic stiffness on survival in end-stage renal disease. Circulation, 99, 2434-2439.
3. BOUTOUYRIE, P., BUSSY, C., LACOLLEY, P., GIRERD, X., LALOUX, B. & LAURENT, S. (1999). Association between local pulse pressure, mean blood pressure, and large-artery remodeling. Circulation, 100, 1387-1393.
4. BROWNLEE, M., CERAMI, A. & VLASSARA, H. (1988). Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med., 318, 1315-1321.
5. CANTINI, C., KIEFFER, P., CORMAN, B., LIMINANA, P., ATKINSON, J. & LARTAUD-IDJOUADIENE, I. (2001). Aminoguanidine and aortic wall mechanics, structure, and composition in aged rats. Hypertension, 38, 943-948.
6. CHAN, V., HOEY, A. & BROWN, L. (2006). Improved cardiovascular function with aminoguanidine in DOCA-Salt hypertensive rats. Br. J. Pharmacol, 148, 902-908 (this issue).
7. COCKCROFT, J.R., WEBB, D.J. & WILKINSON, I.B. (2000). Arterial stiffness, hypertension and diabetes mellitus. J. Hum. Hypertens., 14, 377-380.
8. CORMAN, B., DURIEZ, M., POITEVIN, P., HEUDES, D., BRUNEVAL, P., TEDGUI, A. & LEVY, B.I. (1998). Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. Proc. Natl. Acad. Sci. U.S.A., 95, 1301-1306.
9. CRUICKSHANK, K., RISTE, L., ANDERSON, S.G., WRIGHT, J.S., DUNN, G. & GOSLING, R.G. (2002). Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation, 106, 2085-2090.
10. FRANKLIN, S.S., JACOBS, M.J., WONG, N.D., L'ITALIEN, G.J. & LAPUERTA, P. (2001). Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on national health and nutrition examination survey (NHANES) III. Hypertension, 37, 869-874.
11. FREEDMAN, B.I., WUERTH, J.P., CARTWRIGHT, K., BAIN, R.P., DIPPE, S., HERSHON, K., MOORADIAN, A.D. & SPINOWITZ, B.S. (1999). Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control. Clin. Trials, 20, 493-510.
12. GUERIN, A.P., BLACHER, J., PANNIER, B., MARCHAIS, S.J., SAFAR, M.E. & LONDON, G.M. (2001). Impact of aortic stiffness attenuation on survival of patients in end- stage renal failure. Circulation, 103, 987-992.
13. KASS, D.A., SHAPIRO, E.P., KAWAGUCHI, M., CAPRIOTTI, A.R., SCUTERI, A., DEGROOF, R.C. & LAKATTA, E.G. (2001). Improved arterial compliance by a novel advanced glycation endproduct crosslink breaker. Circulation, 104, 1464-1470.
14. LAURENT, S., BOUTOUYRIE, P., ASMAR, R., GAUTIER, I., LALOUX, B., GUIZE, L., DUCIMETIERE, P. & BENETOS, A. (2001). Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension, 37, 1236-1241.
15. LI, Y.M., STEFFES, M., DONNELLY, T., LIU, C., FUH, H., BASGEN, J., BUCALA, R. & VLASSARA, H. (1996). Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc. Natl. Acad. Sci. U.S.A., 93, 3902-3907.
16. MCENIERY, C.M., YASMIN, HALL, I.R., QASEM, A., WILKINSON, I.B. & COCKCROFT, J.R. (2005). Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J. Am. Coll. Cardiol., 46, 1753-1760.
17. MEAUME, S., BENETOS, A., HENRY, O.F., RUDNICHI, A. & SAFAR, M.E. (2001). Aortic pulse wave velocity predicts cardiovascular mortality in subjects 470 years of age. Arterioscler. Thromb. Vasc. Biol., 21, 2046-2050.
18. MIZUTANI, K., IKEDA, K., TSUDA, K. & YAMORI, Y. (2002). Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats. J. Hypertens., 20, 1607-1614.
19. NIELSEN, W.B., VESTBO, J. & JENSEN, G.B. (1995). Isolated systolic hypertension as a major risk factor for stroke and myocardial infarction and an unexploited source of cardiovascular prevention: a prospective population-based study. J. Hum. Hypertens., 9, 175-180.
20. OOSHIMA, A. & MIDORIKAWA, O. (1977). Increased lysyl oxidase activity in blood vessels of hypertensive rats and effect of beta-aminopropionitrile on arteriosclerosis. Jpn. Circ. J., 41, 1337-1340.
21. SAFAR, M.E., BLACHER, J., PANNIER, B., GUERIN, A.P., MARCHAIS, S.J., GUYONVARC'H, P.M. & LONDON, G.M. (2002). Central pulse pressure and mortality in end-stage renal disease. Hypertension, 39, 735-738.
22. STAESSEN, J.A., GASOWSKI, J., WANG, J.G., THIJS, L., DEN HOND, E., BOISSEL, J.P., COOPE, J., EKBOM, T., GUEYFFIER, F., LIU, L., KERLIKOWSKE, K., POCOCK, S. & FAGARD, R.H. (2000). Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet, 355, 865-872.
23. SUTTON-TYRRELL, K., NAJJAR, S.S., BOUDREAU, R.M., VENKITACHALAM, L., KUPELIAN, V., SIMONSICK, E.M., HAVLIK, R., LAKATTA, E.G., SPURGEON, H., KRITCHEVSKY, S., PAHOR, M., BAUER, D. & NEWMAN, A. (2005). Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation, 111, 3384-3390.
24. VAITKEVICIUS, P.V., LANE, M., SPURGEON, H., INGRAM, D.K., ROTH, G.S., EGAN, J.J., VASAN, S., WAGLE, D.R., ULRICH, P., BRINES, M., WUERTH, J.P., CERAMI, A. & LAKATTA, E.G. (2001). A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc. Natl. Acad. Sci. U.S.A., 98, 1171-1175.
25. WILLIAMS, B. (2005). Differential impact of blood pressure-lowering drugs on central arterial pressure influences clinical outcomes - principle results of the conduit artery function evaluation study in ASCOT. Circulation, 112, 3362.
26. WOLFFENBUTTEL, B.H., BOULANGER, C.M., CRIJNS, F.R., HUIJBERTS, M.S., POITEVIN, P., SWENNEN, G.N., VASAN, S., EGAN, J.J., ULRICH, P., CERAMI, A. & LEVY, B.I. (1998). Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc. Natl. Acad. Sci. U.S.A., 95, 4630-4634.